{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:35Z","timestamp":1790787155201,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic disease occurring in several underlying conditions. Drug\u2010associated AHA (D\u2010AHA) is poorly addressed nowadays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This work aims to identify and characterize which drugs are associated with AHA using the WHO global database of reported potential effects of medicinal products (VigiBase).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      First, we realized a disproportionality analysis using the information component (IC) to identify D\u2010AHA in VigiBase. IC compares observed\u2010 and expected\u2010values in order to find associations between drugs and adverse drug reactions (ADRs) using disproportionate Bayesian reporting. IC\n                      <jats:sub>025<\/jats:sub>\n                      is the lower end of a 95% credibility interval for the IC. Then, we collected cases of drugs significantly associated with AHA from July 2004 to November 2021.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      14 drugs with IC\n                      <jats:sub>025<\/jats:sub>\n                      &gt; 0 were identified representing a total of 185 cases. D\u2010AHA occurred more frequently in men (59%) than women (41%). The median (min\u2013max) age at onset was 75 years (8\u201398). The median [Q1\u2013Q3] time to onset of D\u2010AHA from the start of the suspected drug was 30 days [9.5\u201373.75] and 10% of cases resulted in a fatality. The drugs associated with the highest IC\n                      <jats:sub>025<\/jats:sub>\n                      (IC\n                      <jats:sub>025<\/jats:sub>\n                      &gt; 2) were Clopidogrel, Alemtuzumab, Omalizumab. This study retrieved for the first time three usually used drugs (3\/14) that exhibit a significant pharmacovigilance signal for D\u2010AHA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This worldwide pharmaco\u2010epidemiologic study updates the list of the drugs associated with AHA. The clinician should be aware of these possible severe ADR, which might require larger epidemiological and pathophysiologic studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.14692","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T11:40:17Z","timestamp":1668166817000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Drug\u2010associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database"],"prefix":"10.1111","volume":"29","author":[{"given":"Konstantin","family":"Konstantinov","sequence":"first","affiliation":[{"name":"Haematology Laboratory CHU Caen Normandie  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[{"name":"UNICAEN, EA4650 SEILIRM CHU de Caen Normandie Normandie University  Caen France"},{"name":"Department of Pharmacology CHU de Caen Normandie  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gillet","sequence":"additional","affiliation":[{"name":"Haematology Laboratory CHU Caen Normandie  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[{"name":"UNICAEN, EA4650 SEILIRM CHU de Caen Normandie Normandie University  Caen France"},{"name":"Department of Pharmacology CHU de Caen Normandie  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine UNICAEN CHU de Caen Normandie Normandie University  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Deshayes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine UNICAEN CHU de Caen Normandie Normandie University  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-3858","authenticated-orcid":false,"given":"Yohann","family":"Repesse","sequence":"additional","affiliation":[{"name":"Haematology Laboratory CHU Caen Normandie  Caen France"},{"name":"Unicaen, Inserm, Physiopathology and Imaging of Neurological Disorders (PhIND) Normandie University  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24777"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-387025-4.00003-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00733.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04654.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20390"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1980.53.5.0600"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466"},{"issue":"4","key":"e_1_2_10_10_1","first-page":"55","article-title":"Drug\u2010Induced anti\u2010factor VIII antibodies: a systematic review","volume":"13","author":"Franchini M","year":"2007","journal-title":"Med Sci Monit"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"issue":"2","key":"e_1_2_10_12_1","first-page":"1","article-title":"Alemtuzumab\u2010related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset","volume":"6","author":"Yap SM","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.09.022"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129697"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0686-9"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0024"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.21"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-001-0308-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2273-6"},{"key":"e_1_2_10_20_1","first-page":"1","article-title":"A case of acquired haemophilia A in a 70\u2010year\u2010old post COVID\u201019 vaccine","volume":"1","author":"Lemoine C","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15291"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004957"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140491"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08890.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26132"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15665"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","unstructured":"MooreD ElmesJ ArnallJ et\u00a0al.Immune checkpoint inhibitor\u2010induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system.Haemophilia.2022;28:e145\u2010e148.https:\/\/doi.org\/10.1111\/hae.14632. [Epub ahead of print]","DOI":"10.1111\/hae.14632"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80007-6"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T18:15:59Z","timestamp":1692296159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/hae.14692"],"URL":"https:\/\/doi.org\/10.1111\/hae.14692","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"2022-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}